Palatin Technologies

Palatin Technologies is a biopharmaceutical company developing targeted receptor-specific peptide therapies for the treatment of diseases with significant unmet medical needs and commercial potential. The company's programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product in clinical development is bremelanotide for the treatment of female sexual dysfunction (FSD). Additionally, the company has candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory conditions.